Founders Capital Management Trims Position in Gilead Sciences, Inc. $GILD

Founders Capital Management trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.8% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 812 shares of the biopharmaceutical company’s stock after selling 200 shares during the period. Founders Capital Management’s holdings in Gilead Sciences were worth $90,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in GILD. Southland Equity Partners LLC increased its stake in Gilead Sciences by 2.9% during the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after buying an additional 92 shares during the period. Twelve Points Wealth Management LLC increased its stake in Gilead Sciences by 1.5% during the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock worth $721,000 after buying an additional 98 shares during the period. Argentarii LLC increased its stake in Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 99 shares during the period. Peak Financial Advisors LLC increased its stake in Gilead Sciences by 1.7% during the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock worth $677,000 after buying an additional 100 shares during the period. Finally, Perkins Coie Trust Co increased its stake in Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock worth $435,000 after buying an additional 100 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GILD shares. Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. UBS Group raised their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. JPMorgan Chase & Co. raised their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Finally, Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.17.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares in the company, valued at $12,855,329.01. This trade represents a 2.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $9,402,130 in the last ninety days. 0.27% of the stock is owned by insiders.

Gilead Sciences Trading Down 1.4%

NASDAQ GILD opened at $111.00 on Wednesday. Gilead Sciences, Inc. has a one year low of $82.82 and a one year high of $121.83. The company has a 50-day simple moving average of $114.52 and a 200-day simple moving average of $109.91. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market capitalization of $137.73 billion, a PE ratio of 22.11, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the business posted $2.01 EPS. The company’s quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.